Related Experiment Video
Updated: Jun 23, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Biological drugs for the treatment of children with atopic dermatitis
Mattia Giovannini1,2, Leticia de Las Vecillas3, Maria De Filippo4,5
1Allergy Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Insights
Targeted therapies are improving pediatric atopic dermatitis (AD) management. Key challenges include long-term safety data, biomarker strategies, and equitable access to these advanced treatments for children.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition impacting children's quality of life.
- Advances in understanding AD immunopathogenesis have spurred targeted therapeutic development.
Purpose of the Study:
- To review available and emerging targeted therapies for pediatric AD.
- To connect mechanistic insights with current and future biologics and JAK inhibitors.
- To highlight limitations in pediatric evidence, real-world data, and treatment selection.
Main Methods:
- Literature review of PubMed and clinical trial databases.
- Focus on studies evaluating targeted systemic treatments in pediatric AD patients.
Main Results:
- Targeted therapies are transforming pediatric AD management.
- Improved disease control and quality of life are observed with these treatments.
Conclusions:
- Targeted therapies offer significant benefits for pediatric AD.
- Long-term safety, biomarker-guided strategies, and access remain critical challenges.
Introduction:
Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently affects children and is associated with significant morbidity and impaired quality of life. Recent advances in our understanding of AD immunopathogenesis have led to the development of targeted biological and small-molecule therapies.
Areas Covered:
This review focuses on the available and emerging targeted therapies for pediatric AD, linking mechanistic rationale to currently available and emerging biologics and JAK inhibitors and highlighting the limits of pediatric evidence, real-world data, and treatment selection. The literature was reviewed by searching PubMed and other relevant clinical trial databases, focusing on studies that evaluated targeted systemic treatments in children and adolescents with AD.
Expert Opinion:
Targeted therapies are reshaping the management of pediatric AD and improving disease control and quality of life. However, long-term safety data, validated biomarker-guided treatment strategies, and equitable access to these therapies remain key challenges.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

